{"prompt": "['Trelagliptin-4002', 'Page 33 of 66', 'Version 2.0', 'July 5,10', '8.4', 'Allocation of the study drug and administration procedure', 'The principal investigator or the designee shall access the Case Registration Web System to', 'allocate the study subjects. The principal investigator or the designee shall notify the information', 'required for allocation in addition to the study subject identification (ID) code. Then, drugs that', 'should be administered to each study subject will be notified through the Case Registration Web', 'System. The principal investigator or investigator shall prescribe the study drug or comparative drug', 'according to the notification, and record the drug information (the name, dose per administration,', 'number of daily administration and number of tablets per administration) into the CRF of each', 'research subject.', '8.5', 'Preparation and storage of allocation list', 'The allocation responsible person (designated by the sponsor) shall create an allocation list.', 'Study subjects will be allocated at the Case Registration Center through the Case Registration Web', 'System, using \"the total score for the DTR-QOL Questionnaire [<80% (<168.2 as a score) or >80%', '(2168.2 as a score**) and \"HbAlc (<8.0% or 8.0%)\" at the start of the screening period as', 'stratification factors. The Case Registration Center will use the allocation list for stratification', 'prepared by the allocation responsible person in operating the treatment allocation.', 'Refer to the section 9.1.9 for the calculation method of the total score for the DTR-QOL', 'Questionnaire.', 'Information on the allocation shall be kept in a safe place and shall not be available to anyone other', 'than authorized persons, to secure independency from the clinical research.', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 34 of 66', 'Version 2.0', 'July 5,10', '9.0', 'CLINICAL STUDY PROTOCOL', '9.1', 'Clinical study procedures', 'The principal investigator or investigator shall collect data in accordance with the procedure below.', 'In principle, all the tests, observations, and evaluations of study subjects shall be performed by the', 'same principal investigator or investigator with the exception of the specific 20-lipoprotein fraction.', 'The study schedule is provided in Appendix A.', '9.1.1 Informed consent', 'The procedures for obtaining informed consent are described in Section 15.3.', 'Consent shall be obtained from the study subject before initiation of study procedures.', 'A study subject ID code will be given to each study subject who provided informed consent, and', 'then the study subject is to be de-identified. The study subject ID code shall be used throughout the', 'study period and shall not be changed.', '9.1.2 Demographic data and medical history', 'The following data will be collected as demographic data:', '-', 'Date of birth, sex, smoking history, alcohol intake history, the time (month and year) of diabetes', 'onset (or a diabetes diagnosis)', 'As medical history, the information on clinically problematic diseases and symptoms', 'resolved/recovered within a year before the start of the screening period will be collected. A', 'continuous disease/symptom will be considered as a comorbidity.', '9.1.3 Physical examination', 'The presence/absence of clinically significant abnormalities at subsequent physical examinations', 'during the course of this study treatment will be determined compared with the baseline physical', 'examination.', '9.1.4 Body weight, height, and BMI', 'Body weight shall be measured to one decimal place in kilograms.', 'Height shall be measured to the nearest whole number in centimeters.', 'The sponsor will calculate BMI using the formula below, showing one decimal place.', 'Body Mass Index: BMI=body weight (kg)/[height(m)]\u00b2', '9.1.5 Concomitant drugs', 'Concomitant drugs are all drugs to be given in addition to the study drug or comparative drug. Drugs', 'prescribed by physicians or the over-the-counter medicines purchased by the study subjects shall be', 'included. At every visit of the study subject, any use of drugs (name, dosage/administration, route of', 'CONFIDENTIAL']['Trelagliptin-4002', 'Page 35 of 66', 'Version 2.0', 'July 5, 2017', 'administration, duration of use, and intended use) shall be investigated and recorded on the CRF', 'from the start of the screening period to the completion of the clinical study. In addition, the', 'followings shall be recorded on the CRF; any use of therapeutic drugs for comorbidity * number of', 'daily doses of therapeutic drugs for comorbidities (<2 times or >2 times); and total number of daily', 'tablets of therapeutic drugs for comorbidity (<2 tablets or >2 tablets) from the start of the screening', 'period to the completion of the clinical study.', '* For recording of any use of therapeutic drugs for comorbidity; number of daily doses of', 'therapeutic drugs for comorbidity (<2 times or >2 times); and total number of daily tablets of', 'therapeutic drugs for comorbidity (<2 tablets or >2 tablets), drugs for as-needed use and topical use', 'and supplements are not be included. For drugs for once-weekly use, the numbers shall be divided', 'by 7 for recording.', '9.1.6 Comorbidities', 'A comorbidity shall be defined as a disease or symptom present at the start of the screening period or', 'observed from the start of the screening period until before the start of study drug or comparative', 'drug administration. Clinically problematic laboratory tests and abnormal physical examination', 'findings, etc. observed through the first tests and physical examination at the start of the screening', 'period shall be considered as comorbidities at the discretion of the principal investigator or', 'investigator. The details of comorbidities (diagnoses) shall be investigated.', '9.1.7 Laboratory tests', 'The laboratories will perform the tests shown below in accordance with the Schedule for Study', 'Procedures (Appendix A). The tests will be performed under the >10-hour fasting condition', '(excluding start of observation period). The principal investigator or investigator will retain the', 'reported results of laboratory tests along with evaluating them.', 'CONFIDENTIAL']\n\n###\n\n", "completion": "END"}